B-intervention	0	6	Sector
I-intervention	7	16	resection
I-intervention	17	21	with
I-intervention	22	24	or
I-intervention	25	32	without
I-intervention	33	46	postoperative
I-intervention	47	59	radiotherapy
O	60	63	for
B-eligibility	64	69	stage
I-eligibility	70	71	I
I-eligibility	72	78	breast
I-eligibility	79	85	cancer
O	85	86	:
O	87	89	20
O	89	90	-
O	90	94	year
O	95	102	results
O	103	105	of
O	106	107	a
O	108	118	randomized
O	119	124	trial
O	124	125	.

O	126	128	To
O	129	140	investigate
O	141	144	how
O	145	157	radiotherapy
O	158	159	(
O	159	162	XRT
O	162	163	)
O	164	168	adds
O	169	171	to
O	172	177	tumor
O	178	185	control
O	186	191	using
O	192	193	a
O	194	206	standardized
O	207	215	surgical
O	216	225	technique
O	226	230	with
O	231	241	meticulous
O	242	249	control
O	250	252	of
O	253	261	surgical
O	262	269	margins
O	270	272	in
O	273	274	a
O	275	285	randomized
O	286	291	trial
O	292	296	with
O	297	299	20
O	300	305	years
O	306	308	of
O	309	315	follow
O	315	316	-
O	316	318	up
O	318	319	.

B-total-participants	320	325	Three
I-total-participants	326	333	hundred
I-total-participants	334	340	eighty
I-total-participants	340	341	-
I-total-participants	341	344	one
B-eligibility	345	350	women
I-eligibility	351	355	with
I-eligibility	356	361	pT1N0
I-eligibility	362	368	breast
I-eligibility	369	375	cancer
O	376	380	were
O	381	389	randomly
O	390	398	assigned
O	399	401	to
O	402	408	sector
O	409	418	resection
O	419	423	with
O	424	425	(
O	425	428	XRT
O	429	434	group
O	434	435	)
O	436	438	or
B-control	439	446	without
I-control	447	448	(
I-control	448	451	non
I-control	451	452	-
I-control	452	455	XRT
I-control	456	461	group
I-control	461	462	)
I-control	463	476	postoperative
I-control	477	489	radiotherapy
O	490	492	to
O	493	496	the
O	497	503	breast
O	503	504	.

O	505	509	With
O	510	516	follow
O	516	517	-
O	517	519	up
O	520	527	through
O	528	532	2010
O	532	533	,
O	534	536	we
O	537	546	estimated
O	547	557	cumulative
O	558	568	proportion
O	569	571	of
O	572	582	recurrence
O	582	583	,
O	584	590	breast
O	591	597	cancer
O	598	603	death
O	603	604	,
O	605	608	and
O	609	612	all
O	612	613	-
O	613	618	cause
O	619	628	mortality
O	628	629	.

O	630	633	The
O	634	644	cumulative
B-outcome	645	656	probability
I-outcome	657	659	of
I-outcome	660	661	a
I-outcome	662	667	first
I-outcome	668	674	breast
I-outcome	675	681	cancer
I-outcome	682	687	event
O	688	690	of
O	691	694	any
O	695	699	type
B-outcome	700	705	after
I-outcome	706	708	20
I-outcome	709	714	years
O	715	718	was
B-iv-bin-percent	719	721	30
I-iv-bin-percent	721	722	.
I-iv-bin-percent	722	723	9
I-iv-bin-percent	723	724	%
O	725	727	in
O	728	731	the
O	732	735	XRT
O	736	741	group
O	742	745	and
B-cv-bin-percent	746	748	45
I-cv-bin-percent	748	749	.
I-cv-bin-percent	749	750	1
I-cv-bin-percent	750	751	%
O	752	754	in
O	755	758	the
O	759	762	non
O	762	763	-
O	763	766	XRT
O	767	772	group
O	773	774	(
O	774	780	hazard
O	781	786	ratio
O	787	788	[
O	788	790	HR
O	790	791	]
O	791	792	,
O	793	794	0
O	794	795	.
O	795	797	58
O	797	798	;
O	799	801	95
O	801	802	%
O	803	805	CI
O	805	806	,
O	807	808	0
O	808	809	.
O	809	811	41
O	812	814	to
O	815	816	0
O	816	817	.
O	817	819	82
O	819	820	)
O	820	821	.

O	822	825	The
O	826	833	benefit
O	834	836	of
O	837	849	radiotherapy
O	850	853	was
O	854	862	achieved
O	863	869	within
O	870	873	the
O	874	879	first
O	880	881	5
O	882	887	years
O	887	888	.

O	889	894	After
O	895	897	20
O	898	903	years
O	903	904	,
B-iv-bin-percent	905	907	50
I-iv-bin-percent	907	908	.
I-iv-bin-percent	908	909	4
I-iv-bin-percent	909	910	%
O	911	913	of
O	914	917	the
O	918	923	women
O	924	926	in
O	927	930	the
O	931	934	XRT
O	935	940	group
B-outcome	941	945	died
O	946	954	compared
O	955	959	with
B-cv-bin-percent	960	962	54
I-cv-bin-percent	962	963	.
I-cv-bin-percent	963	964	0
I-cv-bin-percent	964	965	%
O	966	968	in
O	969	972	the
O	973	976	non
O	976	977	-
O	977	980	XRT
O	981	986	group
O	987	988	(
O	988	990	HR
O	990	991	,
O	992	993	0
O	993	994	.
O	994	996	92
O	996	997	;
O	998	1000	95
O	1000	1001	%
O	1002	1004	CI
O	1004	1005	,
O	1006	1007	0
O	1007	1008	.
O	1008	1010	71
O	1011	1013	to
O	1014	1015	1
O	1015	1016	.
O	1016	1018	19
O	1018	1019	)
O	1019	1020	.

O	1021	1024	The
O	1025	1035	cumulative
O	1036	1047	probability
O	1048	1050	of
B-outcome	1051	1064	contralateral
I-outcome	1065	1071	cancer
I-outcome	1072	1074	or
I-outcome	1075	1080	death
O	1081	1083	as
O	1084	1085	a
O	1086	1092	result
O	1093	1095	of
O	1096	1102	cancer
O	1103	1108	other
O	1109	1113	than
O	1114	1120	breast
O	1121	1127	cancer
O	1128	1131	was
B-iv-bin-percent	1132	1134	27
I-iv-bin-percent	1134	1135	.
I-iv-bin-percent	1135	1136	1
I-iv-bin-percent	1136	1137	%
O	1138	1140	in
O	1141	1144	the
O	1145	1148	XRT
O	1149	1154	group
O	1155	1158	and
B-cv-bin-percent	1159	1161	24
I-cv-bin-percent	1161	1162	.
I-cv-bin-percent	1162	1163	9
I-cv-bin-percent	1163	1164	%
O	1165	1167	in
O	1168	1171	the
O	1172	1175	non
O	1175	1176	-
O	1176	1179	XRT
O	1180	1185	group
O	1186	1187	(
O	1187	1189	HR
O	1189	1190	,
O	1191	1192	1
O	1192	1193	.
O	1193	1195	17
O	1195	1196	;
O	1197	1199	95
O	1199	1200	%
O	1201	1203	CI
O	1203	1204	,
O	1205	1206	0
O	1206	1207	.
O	1207	1209	77
O	1210	1212	to
O	1213	1214	1
O	1214	1215	.
O	1215	1217	77
O	1217	1218	)
O	1218	1219	.

O	1220	1222	In
O	1223	1225	an
O	1226	1237	anticipated
O	1238	1241	low
O	1241	1242	-
O	1242	1246	risk
O	1247	1252	group
O	1252	1253	,
O	1254	1257	the
B-outcome	1258	1268	cumulative
I-outcome	1269	1278	incidence
I-outcome	1279	1281	of
I-outcome	1282	1287	first
I-outcome	1288	1294	breast
I-outcome	1295	1301	cancer
O	1302	1304	of
O	1305	1308	any
O	1309	1313	type
O	1314	1317	was
B-iv-bin-percent	1318	1320	24
I-iv-bin-percent	1320	1321	.
I-iv-bin-percent	1321	1322	8
I-iv-bin-percent	1322	1323	%
O	1324	1326	in
O	1327	1330	the
O	1331	1334	XRT
O	1335	1340	group
O	1341	1344	and
B-cv-bin-percent	1345	1347	36
I-cv-bin-percent	1347	1348	.
I-cv-bin-percent	1348	1349	1
I-cv-bin-percent	1349	1350	%
O	1351	1353	in
O	1354	1357	the
O	1358	1361	non
O	1361	1362	-
O	1362	1365	XRT
O	1366	1371	group
O	1372	1373	(
O	1373	1375	HR
O	1375	1376	,
O	1377	1378	0
O	1378	1379	.
O	1379	1381	61
O	1381	1382	;
O	1383	1385	95
O	1385	1386	%
O	1387	1389	CI
O	1389	1390	,
O	1391	1392	0
O	1392	1393	.
O	1393	1395	35
O	1396	1398	to
O	1399	1400	1
O	1400	1401	.
O	1401	1403	07
O	1403	1404	)
O	1404	1405	.

O	1406	1418	Radiotherapy
O	1419	1427	protects
O	1428	1435	against
O	1436	1447	recurrences
O	1448	1454	during
O	1455	1458	the
O	1459	1464	first
O	1465	1466	5
O	1467	1472	years
O	1473	1475	of
O	1476	1482	follow
O	1482	1483	-
O	1483	1485	up
O	1485	1486	,
O	1487	1497	indicating
O	1498	1502	that
O	1503	1506	XRT
O	1507	1513	mainly
O	1514	1524	eradicates
O	1525	1535	undetected
O	1536	1542	cancer
O	1543	1547	foci
O	1548	1555	present
O	1556	1558	at
O	1559	1566	primary
O	1567	1576	treatment
O	1576	1577	.

O	1578	1581	The
O	1582	1589	similar
O	1590	1594	rate
O	1595	1597	of
O	1598	1609	recurrences
O	1610	1616	beyond
O	1617	1618	5
O	1619	1624	years
O	1625	1627	in
O	1628	1631	the
O	1632	1635	two
O	1636	1642	groups
O	1643	1652	indicates
O	1653	1657	that
O	1658	1662	late
O	1663	1674	recurrences
O	1675	1678	are
O	1679	1682	new
O	1683	1689	tumors
O	1689	1690	.

O	1691	1696	There
O	1697	1700	are
O	1701	1710	subgroups
O	1711	1715	with
O	1716	1726	clinically
O	1727	1735	relevant
O	1736	1747	differences
O	1748	1750	in
O	1751	1755	risk
O	1755	1756	.
